| Literature DB >> 28426812 |
Nick Allum1, Agnes Allansdottir2, George Gaskell3, Jürgen Hampel4, Jonathan Jackson3, Andreea Moldovan1, Susanna Priest5, Sally Stares6, Paul Stoneman7.
Abstract
We examine international public opinion towards stem-cell research during the period when the issue was at its most contentious. We draw upon representative sample surveys in Europe and North America, fielded in 2005 and find that the majority of people in Europe, Canada and the United States supported stem-cell research, providing it was tightly regulated, but that there were key differences between the geographical regions in the relative importance of different types of ethical position. In the U.S., moral acceptability was more influential as a driver of support for stem-cell research; in Europe the perceived benefit to society carried more weight; and in Canada the two were almost equally important. We also find that public opinion on stem-cell research was more strongly associated with religious convictions in the U.S. than in Canada and Europe, although many strongly religious citizens in all regions approved of stem-cell research. We conclude that if anything public opinion or 'public ethics' are likely to play an increasingly important role in framing policy and regulatory regimes for sensitive technologies in the future.Entities:
Mesh:
Year: 2017 PMID: 28426812 PMCID: PMC5398703 DOI: 10.1371/journal.pone.0176274
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Attitudes towards stem-cell research in Europe, the United States and Canada.
| Europe | United States | Canada | |||
|---|---|---|---|---|---|
| Embryonic | Non-embryonic | Mean | |||
| Approve with usual levels of government regulation and control | 23 | 28 | 25 | 41 | 36 |
| Approve if more tightly controlled and regulated | 36 | 37 | 37 | 32 | 45 |
| Do not approve except under very special circumstances | 17 | 14 | 15 | 19 | 14 |
| Do not approve under any circumstances | 9 | 7 | 8 | 8 | 4 |
| Don't know | 15 | 14 | 15 | 1 | 0 |
| Base | 10,192 | 10,312 | 1,200 | 1,000 | |
* Not all questions were asked of all respondents, hence the reduced sample sizes in Europe and the U.S.
Attitudes towards stem-cell research by religious attendance.
| More than once a week | Once a week | About once a month | Two times a year or less | |
|---|---|---|---|---|
| Approve | 48 | 63 | 77 | 87 |
| Disapprove | 51 | 35 | 22 | 12 |
| Don’t know | 1 | 1 | 1 | 1 |
| Total | 100 | 100 | 100 | 100 |
| Approve | 49 | 70 | 81 | 86 |
| Disapprove | 49 | 30 | 19 | 14 |
| Don’t know | 2 | 0 | 0 | 1 |
| Total | 100 | 100 | 100 | 100 |
| Approve | 49 | 46 | 56 | 64 |
| Disapprove | 26 | 26 | 24 | 20 |
| Don’t know | 24 | 28 | 20 | 16 |
| Total | 100 | 100 | 100 | 100 |
OLS regression models predicting approval of stem-cell research (unstandardized estimates and t-values).
| (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | |
|---|---|---|---|---|---|---|---|---|---|
| U.S. | 0.34 | 0.41 | 0.45 | 0.44 | 0.32 | 0.22 | 0.43 | 0.44 | 0.30 |
| (13.17) | (16.19) | (16.32) | (15.83) | (11.84) | (7.86) | (18.38) | (18.74) | (12.00) | |
| CAN | 0.36 | 0.37 | 0.37 | 0.36 | 0.26 | 0.22 | 0.40 | 0.39 | 0.29 |
| (13.16) | (13.76) | (13.69) | (13.44) | (9.89) | (7.97) | (17.04) | (16.97) | (11.52) | |
| Religiosity | -0.12 | -0.11 | -0.10 | -0.07 | -0.07 | -0.05 | -0.05 | -0.03 | |
| (-16.82) | (-13.52) | (-11.84) | (-8.61) | (-9.25) | (-7.53) | (-6.93) | (-5.13) | ||
| Relig x U.S. | -0.08 | -0.09 | -0.05 | 0.02 | -0.02 | -0.04 | -0.00 | ||
| (-3.54) | (-4.05) | (-2.14) | (0.95) | (-1.06) | (-2.33) | (-0.16) | |||
| Relig x CAN | -0.03 | -0.03 | -0.02 | 0.00 | 0.00 | -0.03 | -0.02 | ||
| (-1.09) | (-1.37) | (-0.81) | (0.15) | (0.07) | (-1.43) | (-0.83) | |||
| Female | -0.06 | -0.04 | -0.05 | -0.05 | -0.04 | -0.03 | |||
| (-3.69) | (-2.67) | (-3.05) | (-3.64) | (-3.37) | (-2.67) | ||||
| 25–34 | 0.02 | 0.01 | 0.01 | -0.00 | 0.00 | -0.00 | |||
| (0.50) | (0.42) | (0.37) | (-0.02) | (0.02) | (-0.00) | ||||
| 35–44 | 0.05 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | |||
| (1.51) | (0.95) | (0.85) | (0.67) | (0.77) | (0.38) | ||||
| 45–54 | 0.02 | 0.00 | 0.00 | -0.02 | -0.02 | -0.03 | |||
| (0.64) | (0.04) | (0.00) | (-0.55) | (-0.49) | (-0.89) | ||||
| 55–64 | -0.01 | -0.05 | -0.05 | -0.06 | -0.06 | -0.08 | |||
| (-0.22) | (-1.27) | (-1.38) | (-1.80) | (-1.90) | (-2.71) | ||||
| 65+ | -0.01 | -0.04 | -0.04 | -0.04 | -0.04 | -0.06 | |||
| (-0.15) | (-1.12) | (-1.16) | (-1.13) | (-1.20) | (-1.92) | ||||
| High school | 0.07 | 0.06 | 0.07 | 0.02 | 0.02 | 0.01 | |||
| (3.12) | (2.74) | (2.92) | (1.14) | (0.87) | (0.75) | ||||
| College+ | 0.23 | 0.18 | 0.18 | 0.10 | 0.09 | 0.07 | |||
| (9.15) | (7.72) | (7.77) | (4.81) | (4.44) | (3.63) | ||||
| Still studying | 0.22 | 0.18 | 0.18 | 0.09 | 0.08 | 0.07 | |||
| (5.27) | (4.47) | (4.52) | (2.60) | (2.34) | (1.87) | ||||
| EducationDK | 0.04 | 0.02 | 0.02 | 0.00 | -0.00 | -0.01 | |||
| (0.52) | (0.29) | (0.31) | (0.04) | (-0.00) | (-0.14) | ||||
| Moral | 0.24 | 0.20 | 0.13 | ||||||
| (30.35) | (22.46) | (16.29) | |||||||
| Moral x U.S. | 0.25 | 0.17 | |||||||
| (10.11) | (7.01) | ||||||||
| Moral x CAN | 0.14 | 0.12 | |||||||
| (5.19) | (4.39) | ||||||||
| Benefit | 0.56 | 0.62 | 0.59 | ||||||
| (63.07) | (59.06) | (57.09) | |||||||
| Ben x U.S. | -0.16 | -0.31 | |||||||
| (-6.56) | (-11.33) | ||||||||
| Ben x CAN | -0.25 | -0.35 | |||||||
| (-8.90) | (-11.43) | ||||||||
| 0.028 | 0.053 | 0.038 | 0.056 | 0.136 | 0.144 | 0.316 | 0.324 | 0.356 |
t statistics in parentheses. N = 10761
* p < 0.05
** p < 0.01
*** p < 0.001